Filing Flows

Filing Flows › Health Care › Earth Science Tech (ETST)

Earth Science Tech (ETST) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Aug 7, 2026 · Earth Science Tech (ETST) Q1 FY27 earnings results →

Q1 FY27 Revenue up 3% year over year to $9.0M · 8¢ of every $1 of revenue kept as net profit · operating margin 10.6%

Earth Science Tech made $9.0M in Q1 FY27 (+3% Y/Y): Sale of Pharmaceutical Products and Medical Consultations $9.0M, Other Revenue $31K. Operating margin 10.6%, net earnings $716K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.

Revenue$9.0M
Year over year+3%
Operating margin10.6%
Net earnings$716K
Operating cash flow$707K

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $9.0M in Q1 FY27, up 3% year over year and down 5% from the previous quarter. Sale of Pharmaceutical Products and Medical Consultations was the largest line at 100% of revenue. Sale of Pharmaceutical Products and Medical Consultations added $245K year over year (up 3%), 92% of the total change.

Gross margin was 69.5%, unchanged from Q1 FY26. Operating profit was $1.0M, a 10.6% margin (up 5.4 points year over year). Of the extra revenue versus Q1 FY26, 189% reached operating profit, above the 5% margin then. Operating expenses fell 6% while revenue rose 3%. Net earnings were $724K, up 56% year over year. The effective tax rate was 25.3%.

Operating cash flow was $707K (up 108% year over year), 99% of net earnings. Non-cash charges added back $67K of depreciation and amortization. Working capital and other items used $75K. Capital expenditures of $41K left free cash flow of $666K.

Quarterly history

Earth Science Tech revenue by quarterEarth Science Tech revenue by quarter$7.4MQ3 FY25$8.7MQ4 FY25$8.8MQ1 FY26$9.1MQ2 FY26$8.4MQ3 FY26$9.5MQ4 FY26$9.0MQ1 FY27
Earth Science Tech net earnings by quarterEarth Science Tech net earnings by quarter$206KQ3 FY25$1.2MQ4 FY25$457KQ1 FY26$967KQ2 FY26$910KQ3 FY26$1.3MQ4 FY26$716KQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QAug 7, 2026$9.0M+3%10.6%$716K$707K
Q4 FY2610-KJun 18, 2026$9.5M+10%6.8%$1.3M$886K
Q3 FY2610-QFeb 13, 2026$8.4M+14%16.0%$910K−$126K
Q2 FY2610-QNov 12, 2025$9.1M+6%10.5%$967K$842K
Q1 FY2610-QAug 8, 2025$8.8M+2%5.2%$457K$339K
Q4 FY2510-KJun 27, 2025$8.7M+44%14.5%$1.2M$2.0M
Q3 FY2510-QFeb 14, 2025$7.4M+94%3.1%$206K$500K

Charts

Earth Science Tech: revenue growth, year over year and quarter over quarterEarth Science Tech: revenue growth, year over year and quarter over quarterY/YQ/Q+94%Q3 FY25+44%+18%Q4 FY25+2%+1%Q1 FY26+6%+3%Q2 FY26+14%-7%Q3 FY26+10%+13%Q4 FY26+3%-5%Q1 FY27
Latest (Q1 FY27): Y/Y +3%, Q/Q -5%.
Earth Science Tech: where the cash came from (+) and went (−), TTM to Q1 FY27Earth Science Tech: where the cash came from (+) and went (−), TTM to Q1 FY27Operating cash flow$2.3MOther investing−$1.2MBuybacks−$783KCapital spending−$566KCash drawn (+) / kept (−)$246KOther financing−$55K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Earth Science Tech: profit against cash, quarter by quarterEarth Science Tech: profit against cash, quarter by quarterNet incomeOperating cash flow$798K$927KQ2 FY25$206K$500KQ3 FY25$1.2M$2.0MQ4 FY25$457K$339KQ1 FY26$946K$842KQ2 FY26$910K−$126KQ3 FY26$1.3M$886KQ4 FY26$716K$707KQ1 FY27
Latest (Q1 FY27): Net income $716K, Operating cash flow $707K.
Earth Science Tech: diluted shares by fiscal year (split-adjusted)Earth Science Tech: diluted shares by fiscal year (split-adjusted)292MFY23310MFY24304MFY25293MFY26
+0.5% since FY23: more shares outstanding (issuance, stock pay); earlier years scaled for the 2-for-1 split before FY24.
Earth Science Tech in its industry: growth against margin (225 companies, SIC 2834)Earth Science Tech in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMETST (+3%, 11%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Earth Science Tech

Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010, and subsequently redomiciled to the State of Florida on June 27, 2022, headquartered in Miami, Florida. ETST operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.

In its own words, from its 10-K, filed Jun 18, 2026.

Earth Science Tech against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +3% against the peers' median +7%. Operating margin: 10.6% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
ETST Earth Science TechQ1 FY27$9.0M+3%10.6%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Earth Science Tech 10-Q on SEC EDGAR · CIK 1538495 · Pharmaceutical Preparations

More on ETST

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare ETST with

中文版：Earth Science Tech（ETST）财报

Español · Français